Title
Category
Credits
Event date
Cost
  • Psychotic Disorders
  • Veterans and Military Issues
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Measurement-based care (MBC) can improve patient outcomes, but data on its use in psychosis are sparse. This study examined the use of patient-reported outcome measures in veterans with psychosis to identify candidate measures for psychosis-related MBC.
  • Alzheimer Disease
  • Dementia
  • Neuroimaging
  • Primary Care
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Early-stage diagnosis of Alzheimer disease leads to prompt treatment initiation and better patient QoL. Learn about new guidelines and technology advances and what’s on the horizon from authorities in the field.
  • Schizophrenia/ Schizoaffective Disorders
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Experts discuss appropriate treatment sequencing for patients with schizophrenia, including early use of LAIs and switching from an oral antipsychotic.
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • Neuroimaging
  • Patient/Physician Communication
  • Primary Care
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
  • Patient/Physician Communication
  • Women’s Mental Health
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Diagnosis and tailored treatment of menstrual cycle- and menopausal-related mood disorders are key factors in helping women live the lives they want to live.
  • Delivery of Care
  • Muscular Dystrophy
  • Neurology
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
A detailed, modern digest of key advances in the diagnosis, treatment, and management of patients with Duchenne muscular dystrophy.
  • Antipsychotics
  • Schizophrenia/ Schizoaffective Disorders
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
What is the future of schizophrenia treatment? An in-depth exploration of novel, non-dopaminergic therapies transforming the standard of care for patients with schizophrenia’s positive and negative symptoms.
  • Depression
  • Mood Disorders
  • Women’s Mental Health
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Early diagnosis of PPD is critical for mother-infant outcomes, and new hypotheses in its pathophysiology has led to novel and emerging therapies that can improve these outcomes.
  • Alzheimer Disease
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Participation
$0.00
New biomarker technology and advancements in treatment options can lead to earlier diagnosis of AD and initiation of appropriate disease modifying therapies.
  • Mood Disorders
  • Women’s Mental Health
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Program IntroductionMood disorders throughout women's reproductive stages require comprehensive care to alleviate unnecessary suffering, comorbidities, and unwanted outcomes.Learning ObjectivesAfter completing this educational activity, you should be able to:

Pages